Anavex Life Sciences Corp (AVXL)

[falconer66a]

Mice Aren’t Men — But Have Same Chemistries

The mice aren’t men crowd will, once again, so thoroughly tell us that these results, like all the other positive therapeutic outcomes in murine populations with biochemistries and pathologies parallel to human diseases (in this case, tuberous sclerosis), simply can’t and don’t predict human efficacies for any Anavex drug.

Well enough, for those who want to base their considerations of AVXL equities on such perspectives.

It is noted that here, once again — now for a new pathology –- Anavex 2-73 yields very positive therapeutic outcomes in diseased mice.

The significance? There has been not yet a single Anavex-in-mice study that didn’t yield positive therapeutic outcomes. Not a single, published failure yet.

This is further evidence of the wide base of central nervous system (and other) diseases Anavex 2-73 has proven potentials against. It won’t be just Rett, Alzheimer’s, and Parkinson’s.

From the conference poster:

Collectively, these results suggest a role for ANAVEX2-73 as a potential treatment for a wide range of diseases, including rare neurodevelopmental diseases, that elicit seizures.